Sally Arai MD

Hematology•Stanford, CA

Hematologic Oncology

Assistant Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to View Full Profile

300 Pasteur DrStanford, CA 94305
Phone+1 650-723-0822

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1995 - 1998
University of Rochester Medical CenterResidency, Internal Medicine, 1992 - 1995
George Washington UniversityResidency, Surgery, 1991 - 1992
Geisel School of Medicine at DartmouthClass of 1991

Certifications & Licensure

CA State Medical License 2004 - 2025
IL State Medical License 2001 - 2005
MD State Medical License 1999 - 2004
NY State Medical License 1994 - 2004
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma Start of enrollment: 1994 Sep 01
Completed
Phase 2
High Dose Chemotherapy Followed By PBSC Rescue for HD Start of enrollment: 1998 Mar 01
Completed
Not Applicable
Autologous Stem Cell Rescue for Primary Amyloidosis Start of enrollment: 1998 Apr 01
Completed
Phase 2
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma Start of enrollment: 2006 Aug 01
Completed
Phase 2
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease Start of enrollment: 2006 Aug 01
Completed
Not Applicable
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Start of enrollment: 2001 Sep 01
Completed
Phase 2
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies Start of enrollment: 2006 May 01
Completed
Phase 1
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Start of enrollment: 2009 Aug 01
Completed
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
Completed
Phase 2
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
COMPLETED
PHASE1, PHASE2
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Start of enrollment: 2013 Jul 01
Completed
Phase 1
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies Start of enrollment: 2021 Jun 16
TERMINATED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Efficacy of hedgehog pathway inhibitors as adjuvant in treating steroid-refractory sclerodermatous chronic graft-versus-host disease.
Andres Mendez-Hernandez, Ridhi Gupta, Sally Arai, Robert Lowsky, Bernice Kwong
Journal of the American Academy of Dermatology. 2025-05-01
The Impact of Melphalan Conditioning and CD34Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis.
Eli Muchtar, Vaishali Sanchorawala, Hamza Hassan, Ute Hegenbart, Stefan Schönland
American Journal of Hematology. 2025-04-11
Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
Michelle M Chin, John S Tamaresis, Laura J Johnston, Robert Lowsky, Everett Meyer
Bone Marrow Transplantation. 2025-03-01

Abstracts/Posters

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab
Sally Arai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Roberto Alejandro Sica, MD, a Hematologist-Oncologist with Montefiore Medical CenterJanuary 5th, 2022
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
Meet Your Match: A Bone Marrow Transplantation Leads to an International FriendshipMay 10th, 2018